Dual cytokine fusion proteins comprising IL-10

Inventors

Mumm, John

Assignees

Deka Biosciences Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12122814-B2

Patent

Publication Date

2024-10-22

Expiration Date


Abstract

The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.

Core Innovation

The invention relates to dual cytokine fusion proteins defined by formula (I), where a monomeric IL-10 is fused to a second cytokine other than IL-10. The fusion architecture includes antibody-derived regions X1 and X2 arranged as VL or VH regions, with n equal to an integer of 1, and IL-10 is positioned at the N-terminus and at the C-terminus of the fusion protein, with the second cytokine Z incorporated between the antibody regions within the overall construct.

The patent describes an antibody/cytokine fusion architecture in which X1 and X2 are derived from monoclonal antibody regions that include engrafted CDRs. In the disclosed embodiment, the first monoclonal antibody is an anti-Ebola antibody, the second antibody is an anti-PDGFR monoclonal antibody, and the second cytokine Z is IL-2.

The patent further addresses dual-cytokine fusion constructs that use IL-10 monomer and IL-10 variant molecules fused to an scFv VH/VL “Debo” half-life–extended scaffolding, with a second cytokine inserted between the VH and VL in the scFv hinge/linker. The patent states that tethering IL-2 to an IL-10 variant via the scFv linker enhances potency of IFN-γ potentiation while suppressing IL-2–mediated IFN-γ induction and preventing toxicity at therapeutic doses, and that combining IL-4 with IL-10 variants more potently suppresses LPS-induced TNFα in monocytes/macrophages and reduces IFN-γ induction in CD8+ T cells, with a protective effect shown in a mouse sepsis model with increased survival.

Claims Coverage

The independent claim defines a specific dual-cytokine fusion protein architecture by formula (I) with IL-10 as a monomer and a second cytokine incorporated between antibody-derived VL/VH regions, while dependent claims narrow the antibody framework and extend the subject matter to a pharmaceutical composition. One independent claim is provided in the partial claim set.

Dual-cytokine fusion protein of formula (I) with IL-10 monomer and antibody-derived regions

A dual cytokine fusion protein of formula (I) NH2-(IL10)-(X1)-(Zn)-(X2)-(IL10)-COOH, wherein IL-10 is a monomer; X1 is a VL or VH region from a first monoclonal antibody; X2 is a VH or VL region from the first monoclonal antibody with X1 as VL and X2 as VH, or X1 as VH and X2 as VL; Z is a cytokine other than IL-10; and n is an integer of 1.

Anti-Ebola framework with engrafted CDRs and IL-2 as the second cytokine

The fusion protein wherein the first monoclonal antibody is an anti-Ebola antibody; the VL and VH from the anti-Ebola antibody include 3 light chain CDRs and 3 heavy chain CDRs engrafted with 3 light chain CDRs and 3 heavy chain CDRs from a second monoclonal antibody; the IL-10 is SEQ ID No: 1; the second antibody is an anti-PDGFR monoclonal antibody; and Z is IL-2.

The claims cover a dual cytokine fusion protein using monomeric IL-10 at both termini and a non-IL-10 cytokine inserted between antibody-derived VL/VH regions in formula (I), with an anti-Ebola/anti-PDGFR CDR-engrafting arrangement and IL-2 as the illustrated second cytokine.

Stated Advantages

Enhances potency of IFN-γ potentiation.

Suppresses IL-2–mediated IFN-γ induction.

Prevents toxicity at therapeutic doses.

More potently suppresses LPS-induced TNFα in monocytes/macrophages.

Reduces IFN-γ induction in CD8+ T cells.

Provides protective effects in a mouse sepsis model, with increased survival.

Documented Applications

Therapeutic indications including cancer.

Therapeutic indications including inflammatory/immune diseases.

Therapeutic indications including sepsis/septic shock.

A mouse sepsis model with LPS, where DK4_10mCD14DV06 shows protective effects with increased survival.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.